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ABSTRACT 
SAAD, RAHMA, ABDELAZIM., Masters of Science : January : 2020, Public Health 
Title: PATIENT FACTORS ASSOCIAED with ADHERENCE and CHANGE in 
CARDIAC RISK FACTORS AMONG CARDIAC REHABILITATION PATIENTS 
in QATAR 
Supervisor of Thesis: Karam, Adawi and Mohammed, Alhashemi 
Background: cardiovascular disease is the number one killer in Qatar. Cardiac 
rehabilitation (CR) is a cost-effective model of care shown to reduce cardiovascular 
morbidity and mortality by 20%. However, it is vastly underutilized with low 
enrollment and adherence rates. This study aimed to (a) examine the  association 
between number of sessions attended and  change in cardiac risk factors after 
completion of  CR program, and (b) investigate factors associated with  adherence  
Methods: This is a retrospective cohort study, consisted of 714 cardiac patients, aged 
≥18 years, referred to a cardiac rehabilitation program in Qatar. A simple linear 
regression analysis (unadjusted model) was used to assess the association between the 
mean change in each of the following risk factors: cholestrol, low-density lipoprotein 
(LDL), high-density lipoprotein (HDL), and body mass index (BMI and number of 
sessions attended. Then, we adjusted for clinical and sociodemographic factors that 
affect the outcome variable via multiple linear regression analyses.  Logistic regression 
model was used to assess factors associated with adherence. Additionally, a paired 
sample t-test was used to identify mean change in cardiac risk factors pre-post CR and 
link this change to clinical significant cut off values in the literature. An independent 
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sample t-test was used to identify change between groups (adherence vs. no adherence).  
Result: The mean age of the population was 52.7±10.1 years (mean ± SD).  Patients 
referred to CR program were mostly males (n= 641, 89.8%) and non-Qatari (n= 596, 
83.5%), almost one fourth were smokers (n=185, 25.91%), and one fifth (n=128, 
18.8%) were diagnosed with severe depression. The main positive predictor for 
adherence was AACVPR moderate risk [OR=12.71, 95%CI= 7.81-20.68] and high-risk 
level [OR=10, 95%CI= 6.44-17.44]. PCI [OR=0.39, 95%CI= 0.17-0.89] and 
musculoskeletal disease [OR=0.17, 95%CI= 0.03-0.95] were negatively associated 
with adherence. We found clinically significant improvements among adherents to CR; 
10% reduction in total cholesterol level and 15% reduction in low-density lipoproteins. 
Conclusion: This study provides new insights in Qatar setting into the factors that lead 
patients to adhere to their CR sessions. These patient-level variables associated with 
adherence represent opportunities for program directors in identifying patients who are 
less likely to adhere to the program; therefore, develope effective interventions to target 
these patients and consequently improve their health status. 
 
Keywords: Cardiovascular disease, Cardiac rehabilitation, Adherence 
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CHAPTER 1: INTRODUCTION 
Cardiovascular disease (CVD) is "the name given to a group of disorders 
affecting the body's arteries, which may lead to heart attack, stroke, or angina” (1). In 
addition to the high CVD mortality rate, this disease imposes tremendous pressure on 
healthcare resources because individuals with ongoing heart conditions need ongoing 
medical assistance. CVD significantly affects the quality of life for those who suffer 
from this condition, while also reducing their life expectancy (2). Around the globe, 
(CVD) is considered killer number one (3). According to the Qatar health strategy 2017 
and WHO report, 17.7 million people died due to CVDs, which is equal to 31% of all 
deaths around the world (2, 4). Most of these deaths (7.4 million) were due to coronary 
heart disease, and 6.7 million deaths were due to stroke (2). Unfortunately, this number 
is expected to increase to 23.6 million by 2030 (5). 
In the Eastern Mediterranean Region (EMR), CVD is the leading cause of 
disability, accounting for 9.2% of total disability adjusted life years (DALYs) (6). 
Whereas in Qatar, non-communicable diseases(NCDs) are estimated to account for 
69% of all deaths having CVD in the lead, with 27% of mortality, followed by 16% of 
other NCDs and 16% cancer (7). Furthermore, CVD in Qatar is considered the number 
one cause of death from NCDs (2). With this consistency of the CVD burden, countries 
need to implement prevention strategies to manage it and contain the increased 
mortality rates.  
One crucial and essential strategy adopted is the Cardiac Rehabilitation (CR) 
program. CR identified as a “comprehensive Secondary prevention program that is 
medically supervised and designed to improve the physical and emotional condition of 
patients with heart disease” (8). The program is considered a cost-effective model of 
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care that reduces cardiovascular mortality and morbidity by 20% and encourages a 
commitment to regular exercise and healthy habits for risk factor modification to 
establish lifelong cardiovascular fitness (9). According to Hammill and colleagues, 
there is a strong dose-response relationship between the number of sessions attended 
and the long-term outcome of CVD. Not only that, but attending all of the 36 sessions 
entitled by the program resulted in risk reduction in death and myocardial infarction 
(10). Though the CR program is recommended for patients recovery as different studies 
established due to its benefit, participation of eligible patients in the program is low 
such as in Canada with a 20% participation rate and 14% in middle-income countries 
(11).  
Despite all the benefits of the CR program documented in literature, adherence 
rates are suboptimal(12). In Qatar, there is only one CR program with lack of research 
on the factors associated with adherence. Only one qualitative study  explored reasons 
for nonattendance to the CR program without identifying the possible factors associated 
with adherence(13). Hence, this study aimed to (a) identify patients’ factors associated 
with adherence (attending more than or equal to the median number of sessions) to 
cardiac rehabilitation, (b)explore factors associated with adherence to the median 
number of sessions non adherence and the mean change in cardiac risk factors from pre 
to post enrollment in CR program.  
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CHAPTER 2: LITERATURE REVIEW 
Non-communicable diseases (NCDs), known as chronic diseases, are characterized 
by a long duration and small disease progression. NCDs' five main types are 
cardiovascular diseases (CVD), e.g. (coronary heart disease and stroke), type 2 
diabetes, cancer, respiratory diseases, and mental disorders (5). CVD is the leading 
among non-communicable diseases, and it is considered the number one killer 
worldwide(4). Furthermore, over three-quarters of CVD deaths take place in low- and 
middle-income countries (14).  
CVD is defined as a “group of disorders of heart and blood vessels which includes, 
cerebrovascular disease, peripheral arterial disease, rheumatic heart disease, and 
congenital heart disease” (14). In the year 2015, 17.7 million people died due to CVDs, 
which is equal to 31% of all deaths around the world (1). Most of these deaths (7.4 
million) were due to coronary heart disease, and 6.7 million deaths were due to stroke 
(2). Unfortunately, This number is expected to increase to 23.6 million by 2030 (5).  
In the Eastern Mediterranean Region (EMR), the situation could not be better. CVD 
mortality in the EMR, mostly attributable to ischemic heart disease, is expected to 
increase dramatically in the next decade higher than any other region except Africa 
(6). Approximately 58.4% of total deaths in the EMR were attributable to NCDs in 
2015, with the primary cause being CVD (27.4% of total deaths) (6, 15). According to 
the same study, the author identified that the most prominent CVD risk factors in the 
EMR include tobacco consumption, physical inactivity, depression, obesity, 
hypertension, and diabetes mellitus (6).   
 Within the EMR region, Gulf countries (GCC) have a history of high NCDs, 
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including obesity, diabetes, and, most importantly, CVD. Supporting evidence was 
reported in a systematic review of the Prevalence of cardiovascular disease in the Gulf 
region (16). The study stated that, due to the rapid growth of socioeconomic status in 
the GCC countries, lifestyle changed noticeably in terms of fast food consumption 
and the adoption of sedentary behaviors (16). Thus, the rate of CVD and associated 
risk factors increased, and it exceeded the rate of the developed country(16). Besides,  
the number of deaths resulting from ischemic heart disease and hypertensive heart 
disease in the Middle East (including the GCC countries) was 294/100,000, whereas 
the number of disability-adjusted life years (DALYs) resulting from ischemic and 
hypertensive heart disease is 3702/100,000 (16). In Oman and Kuwait, the estimated 
number of death reached (49%) and (46%), respectively, which means almost half of 
the death in both countries was caused by CVD (3, 16). The rate of CVD deaths was 
also high in the region with Saudi Arabia (42%), UAE (38%), Bahrain (32%), and Qatar 
23% (3, 16).  
Glancing at the situation here in Qatar, CVD is considered The number one cause 
of death from non-communicable diseases, as found in other high-income countries (2). 
Adding to this, in one of Benner's studies, he stated that CVD had been the leading 
cause of morbidity and mortality for over 20 years (17). If we tried to dig more into the 
reasons for such a high CVD prevalence rate, we would find various reasons. In recent 
decades, Qatar has been home to one of the most rapidly growing populations. Since 
2002, the population of 275,325 Qatari citizens and 1,9 million expatriates (non-Qatari 
residents) has risen from 750,000 to around 2,5 million (2). Secondly, and finally, the 
rapid development of infrastructure played a major role in changing behaviors and 
lifestyles of the people, leaning more towards unhealthy choices, which over time led 
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to the development of NCDs such as diabetes, obesity, hypertension, and many other 
diseases (2, 18). 
One crucial point to consider is that between the years 2011 and 2013, CVD 
mortality was 8.3 per 100,000 for Qatari males and 4.1 per 100,000 for non-Qatari 
males aged 20-44 years. However, after the age of 45, CVD mortality rose significantly 
to 247 per 100,000 among Qatari males (2). According to Qatar public health strategy 
2017-2022, the prevalence of having three or more cardiovascular risk factors was 
44.9% among the age 18-64 and 70.4% among the age 45-64 (2). Risk factors include 
High body mass index, High blood pressure and high fasting plasma glucose (1, 2)  
Risk factors could be classified into two groups, modifiable and non-modifiable 
risk factors. The modifiable risk factors include physical inactivity, smoking, alcohol 
use, hypertension, obesity, diabetes, and low intake of fruit and vegetables (1). As for 
non-modifiable factors, it includes age, ethnicity, family history, and socioeconomic 
status. As the person advances in age, he becomes more at risk of developing CVD. 
Moreover, the risk of getting a stroke doubles after the age of 55. Also, having 
a low socioeconomic status accompanied by stressful life and having depression or 
anxiety increases the risk of heart disease and stroke (1). Even though there are many 
risk factors associated with coronary heart disease and stroke, a person will not develop 
CVD if he has only one risk factor. The more risk factors the person has, the higher the 
likelihood that he will develop CVD (1). As CVD requires a continual support-
specifically people who suffer from ongoing heart condition- and may affect the overall 
quality of life (1), policy makers in Qatar realized the need to mitigate the problem of 
high CVD rate by developing strategies with a primary goal to promote healthy 
behaviors in order to reduce controllable risk factors and also to develop an effective 
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screening programs that identify people who are most at risk(2). Thus, one of the 
secondary preventions done in Qatar for patients who suffer from heart diseases is the 
cardiac rehabilitation program.  
Before tackling the situation in Qatar, it is essential to have a holistic 
understanding of how cardiac rehabilitation started. Over the last four decades, CR has 
advanced from a simple monitoring program that helps patients return to their regular 
physical activity, to more of a multidisciplinary secondary prevention program, which 
included various components that can affect patients’ outcomes. These components are 
the following: patient assessment, nutritional counseling, physical activity counseling, 
weight management, smoking cessation, blood pressure management, and lipid 
management (8, 19).  Back in the 1930s, myocardial infarction (MI) patients were 
advised to take six weeks of bed rest. Then, they were advised to take a short daily walk 
of 3-5 minutes after coronary events by four weeks (19). Even though this proved to be 
effective, there was a concern regarding patient safety due to unsupervised exercise(20). 
Hence, this concern leads to the development of a more structured, physician-
supervised rehabilitation program (20) that can help patients optimize their functional 
health (19).  
 By the 1950s, Hellerstein presented his comprehensive multidisciplinary 
procedure for the rehabilitation of patients recovering from an acute cardiac event(21). 
His approach was adopted worldwide and has been recommended as an indispensable 
therapeutic tool in modern cardiology by most cardiovascular professional societies(19, 
22, 23). Even though his approach resulted in excellent outcomes for patients, his 
approach was not translated in a tremendous commendation by the cardiology 
community, and it was not improved significantly. However, due to changing patient 
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demographics and advanced medical technology, many more patients now have the 
opportunity to receive the benefits offered by cardiac rehabilitation (20).  
Cardiac rehabilitation (CR) is defined as a “Comprehensive exercise, education, 
and behavior modification program designed to improve the physical and emotional 
condition of patients with heart disease”, another definition presented by the American 
Heart Association is that “Cardiac rehabilitation and secondary prevention services are 
comprehensive, long term programs involving medical evaluation, prescribed exercise, 
cardiac risk factor modification, education, and counselling. These programs are 
designed to limit the physiological and psychological effects of cardiac illness, reduce 
the risk for sudden death or re-infarction, control cardiac symptoms, stabilize or reverse 
the atherosclerotic process, and enhance the psychosocial and vocational status of 
selected patients” (8).   
The primary goal of the CR program is to enable patients to achieve optimal 
physical, psychological, social, and vocational functioning through exercise training 
and lifestyle changes (24). The short term goals of such programs are classified in short- 
and long-term goals. The Short-term goals reflect "reconditioning" the patient 
sufficiently enough, allowing him to resume customary activities, decrease the risk of 
sudden cardiac arrest, or reinfarction, and finally help control the symptoms of cardiac 
disease. The long-term goals consist of identification and treatment of risk factors, 
stabilizing the atherosclerotic process, and enhancing the psychological status of the 
patients (24).  
In Qatar, there is only one CR program that was developed in July 2013 (24). 
Patients who are eligible to be enrolled in this program are those who have, myocardial 
infarction, coronary artery bypass surgery (CABG), percutaneous transluminal 
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coronary angioplasty (PTCA/PCI), heart or a heart-lung transplant, and heart failure 
(25). They are advised to enroll by the  inpatient cardiac rehab staff at the hospital, 
which is phase I, where they get an assessment along with education on risk factors and 
a discharge plan. In phase II (outpatient), referred patients go through a structured 
program including physical exercise to improve CVD fitness, education about heart 
disease as well as counseling on how to stabilize or reverse heart disease by improving 
the risk factors. The last stage is stage III, consisting of a maintenance program held in 
the community (not in the cardiac center), not yet available in Qatar (24). 
Once patients are referred to the CR program in a heart hospital, the healthcare 
team contacts them to book an appointment for an initial assessment. Based on the 
program protocol, the period between referral initiation and patient enrollment (waiting 
time) should not exceed 60 days (26). Initial assessment includes six different 
procedures as prescribed in the hospital protocol:  
1. Clinical history of Cardiovascular, physical activity, vocational, 
musculoskeletal, and psychosocial status.  
2. Adherence to medication, self-monitoring, smoking status 
3. Physical examination, including vital signs, electrocardiogram (ECG), BMI, 
waist circumferences (WC), waist to hip ratio, heart failure signs, cardiac, 
and neurological abnormalities. 
4. Assessment of routine testing, including full blood count, fasting blood 
sugar, HbA1c, total cholesterol, LDL, and HDL. 
5. “Exercise capacity which includes symptom-limited exercise testing, either 
on the treadmill or bicycle ergometer.” 
6. “Nutrition assessment where healthcare team reviews medical and dietary 
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history, eating patterns measured by food frequency questionnaire and 24-
hour recall method, anthropometric measurements, and behavioral patterns.” 
Formerly, as the initial assessment is done and the patient's results are in, risk  
level (low, moderate, high) will be determined based on a combination score of patient's 
cardiac and metabolic fitness. After patients are classified, the goals of rehabilitation 
are discussed and agreed on, and the patient can take a written plan of his goal. The 
cardiac rehabilitation program duration is three months. Based on evidence reported by 
literature, 36 exercises can result in significant positive changes in exercise capacity, 
cardiovascular risk factors, and quality of life(26, 27). Worldwide CR programs do not 
prescribe CR sessions and that cardiac patients are allowed to take up to 36 sessions or 
more depending on their health condition and coverage by a health insurance company. 
Some programs give sessions over 12 months and others 3-6 months with 3-5 sessions 
per week depending on their capacity (28).In Qatar, the same protocol is followed. After 
identification of the risk level for each patients and based on guideline recomendation, 
a direct supervision of the exercise should occur for at least 6-18 sessions for low risk,  
for those with moderate risk, direct supervision should occur for at least 12 to 24 
sessions and high-risk patients should be monitored for at least 18 to 36 exercise 
sessions (29). Furthermore, patients can take more sessions as long as it is safe to 
remove the ECG monitoring during exercise. Differences and variability in provided 
CR services were explained in a recent study published in the Lancet Journal. The study 
indicated that since the CR program is a multi-component and complex intervention, 
the nature of the services provided may vary widely across programs (30).  
 At discharge, the patient will have a final assessment where physical activity 
level, vital signs, blood testing is checked, as well as a return to work- whether the 
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patient is in good condition to pursue his previous work (26).  
Attending the CR session was proved to be effective. Several meta-analyses 
were conducted to identify the effectiveness of cardiac rehabilitation. Studies showed 
that, among patients with coronary heart disease, exercise-based CR reduces 
hospitalization by a mean of 31%, cardiac mortality by a mean of 20%, and all-cause 
mortality by a mean of 19% (9). Another meta-analysis showed that participation in the 
CR program reduces risk factors of CVD and decreases mortality and morbidity (10). 
Philip and colleagues (2009) stated that participation in CR leads to a 13% (HR, 0.88; 
95% CI, 0.83–0.93) to 24% (HR, 0.77; 95% CI, 0.69–0.87) reduction in mortality over 
1 to 3 years, in addition to a reduction in rehospitalization by 31% (HR, 0.69; 95% CI, 
0.58–0.81) (31) The most important benefit is the increase in physical function and 
quality of life. However, with all of the evidence that CR is effective, still, CR services 
are grossly underutilized with low adherence rates (32). It is essential to identify what 
could be the factors mediating the suboptimal use of these programs; whether it is due 
to the low availability of CR services, provider factors, or related to patient factors. 
Based on a study done by Turk-Adawi and colleagues (2014) on the global 
availability of CR, the CR program was poorly implemented globally. Only 38.8% of 
the world’s countries have CR programs. Precisely, 68.0% of high-income countries  
and 23.0% of low- and middle-income countries, (28.2% for middle- and 8.3% for low-
income countries) (33). The aurhors concluded that low availability of the program 
contributes to  its underutilization worldwide (33). Moreover, three interrelated factors 
were reported in the literature to be associated with CR underutilization; these include: 
patient, provider, and system (32, 34, 35). Within the global context,  Qatar, has only 
one CR program similar to the global trend of low availability. However, there is no 
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study that has explored the program’s utilization in terms of adherence to the program, 
taking into consideration that it is free for elligable patients.    
Patients factors associated with adherence to CR program were reported in one 
of the studies that aimed at identifying patient and organizational factors that keep 
patients in the program. Several CR facilities (n=38) were surveyed, and 4412 records 
of patients enrolled were included in the study. The study showed that patients over the 
age of 65 years, classified as high-risk category (based on classification of American 
Association of Cardiovascular and Pulmonary Rehabilitation AACVPR), receiving 
coronary artery bypass grafting (GABG), and diagnosed with diabetes were  
significantly associated with increase in adherence to the CR program (32). 
Organizational factors were offering relaxation training and individual and group diet 
classes (32). Another study on enrollment showed that enrollment rate was 30% among 
a cohort of (n=6874) patients. Factors associated with patient enrollment in the program 
were undergoing CABG and having health insurance (34). In Qatar, there is a lack of 
research on the program’s utilization and factors associated with its utilization and 
whether these factors are similar to those in literature. 
Furthermore, a systematic review of factors associated with attending cardiac 
rehabilitation revealed that older patients with lower income and suffering from 
depressive symptoms were less likely to attend their sessions. The authors suggested 
that the best way to encourage patients to attend is to address the misconception about 
the program, show how effective it is, and engage physicians to recommend it (36).  
To improve patients utilization of a beneficial program, such as CR program, it 
is crucial that healthcare providers, program directors and policy makers are aware of 
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barriers faced  by patients that prevent them from using the offered services effeciantly. 
A qualitative study conducted in Qatar looked at the reasons for not attending the 
program (13). The most common reasons highlighted by patients were: exercising at 
home, work commitment, transportation, no need for rehabilitation, family 
responsibility and finally a preference to take care of their health alone (13). Building 
on these results, there is a need for a quantitative baseline study to explore adherence 
to CR and to  identify patient factors associated with it. Findings of such study is 
expected to inform policy makers about CR situation and interven in the best possible 
way to improve adherence rate and consequently patients health.   
A recent systematic review and meta-analysis of interventions to promote 
patient’s utilization of the CR program concluded that several interventions could 
increase enrollment, adherence, and completion rates of CR sessions. Face to face 
delivery by healthcare providers was recommended to increase enrollment, while 
offering unsupervised CR sessions would promote adherence considerably (37). 
Patients always look for the benefits gain from any program attended. It was 
proved that adhering to CR is related to the magnitude of clinical benefits. Hammill and 
colleague's study focused on the relationship between cardiac rehabilitation and long-
term risk of death and myocardial infarction among elderly Medicare patients ≥65 
living in the United States (10). Thirty thousand one hundred sixty-one elderly patients 
were included between the first of January 2000 to 31 December 2005. They were 
interested in the exposure to cardiac sessions given in 3 categories, i.e 36, 24,12 
sessions. They found that those who attended 36 sessions had a 14% lower risk of death 
(HR,0.86 95% CI 0.77–0.97) compared to patients who attended 24 sessions, a 22% 
lower risk of death compared to those who attended 12 sessions (HR, 0.78; 95% CI, 
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0.71–0.87) and a 47%  lower risk of death compared to patients who attended 1 session 
only. Thus, this shows that there is a dose-response relationship between the number of 
CR sessions attended and patients long-term outcomes. Moreover, it shows how 
attending more sessions is associated with a lower risk of death compared to attending 
fewer sessions (10).  
A recent study tackled the improvement of secondary prevention measures 
among cardiac rehabilitation patients; specifically among males and female to 
understand if there is a gender disparity (38). The results showed significant 
improvement in total cholesterol level, diastolic blood pressure, and HbA1c. A 10% 
reduction were observed in cholesterol level as well as LDL. These changes were 
proved to be clinically significant in reducing the risk of coronary heart disease. A 
systematic review and meta-analysis showed that having a reduction of 10% in 
cholesterol level is associated with a 15% reduction in risk of coronary heart 
disease(39). Another meta-analysis reported a 7.2% reduction in risk of coronary heart 
disease deaths and 4.4% total deaths if a reduction of 10% of LDL was found (40).  
While having evidence of the benefit of CR sessions, the service is still 
underutilized, and there is lower enrollment, referral, and adhered rate. Thus, it is 
essential to explore the situation from different contexts and settings. 
Multiple studies have been done on factors associated with enrollment and 
adherence to CR in addition to change cardiac risk factors pre-post the program. 
Recommendation from these studies suggested to identify patient characteristics 
associated with uptake and adherence to cardiac rehabilitation in different countries. 
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With the high rate of CVD in Qatar, adhering to CR programs is crucial in this 
context and studying the related factors will contribute to the improvement CR services 
and thus patients’ clinical outcomes. Since there are no studies done in Qatar on either 
of these topics, the current study aimed to fill this gap and address patient factors related 
to adherence and its association with change in risk factors.  
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CHAPTER 3: STUDY OBJECTIVES 
3.1 Objectives  
1. To describe the characteristics of patients participated in the program  
2. To  identify patients factors associated with adherence to CR program and patient 
sociodemographic and clinical factors including age, gender, nationality, tobacco 
use, patients indications  (mentioned above), depression, exercise capacity (MET), 
comorbid conditions such as diabetes miletus (DM), hypertension (HTN), back 
pain, and musculoskeletal disease. Other patient factors to be assessed are BMI, 
SBP, cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), 
and glucose (HbA1c) for patients with diabetes  
3. To examine the relationship between number of sessions attended, and the mean 
change in cardiac risk factors (Cholesterol, LDL, HDL, and BMI)  
4. To examine the relationship between adherence, and the mean change in cardiac 
risk factors (Cholesterol, LDL, HDL, and BMI) after completion of  CR program 
and identify clinically significant clinical measures 
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3.2 Research questions 
This study is based on three research questions: 
1. What is the relationship between patient factors and patient adherence to the 
CR program in Qatar? 
2. Is there a relationship between adherence to CR and the mean change in 
cardiac risk factors (SBP, cholesterol, LDL, HDL, and BMI) from pre to post 
CR program? 
3. Is there a relationship between number of sessions attended and the change in 
cardiac risk factors (Cholesterol, LDL, HDL, and BMI) after completion of  
CR program? 
 
3.3 Hypothesis  
1. There is a relationship between patient’s sociodemographic and clinical factors 
and patient adherence to a CR program  
2. There is a positive relationship between number of CR sessions attended and   
improvement in the level of cardiac  risk factors at program discharge (post-
program) 
3. Adhering to CR sessions is associated with the change in CVD risk factors at 
program discharge 
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CHAPTER 4: METHODS 
4.1 Study design  
Based on our study objectives, the second and third objectives were achievable through 
a cross sectional  study, based on patients’ records, i.e.secondary data),while the fourth 
objective achieved through retrospective cohort study. Our study cohort included all 
patients aged 18 years and over who were referred to a cardiac rehabilitation program 
in Qatar.  
4.2 Data collection methods 
The study is based on a secondary dataset collected by the CR professionals in the 
cardiac rehabilitation program and entered in their internal system. We extracted these 
data for patients from the inception of the program from January 2013 to September 
2018.  The data included sociodemographic variables and clinical and behavioral 
measures that were collected at patient entry (pre-CR) and patient discharge from the 
program (post-CR). Patients who did not attend the first session of the program (non-
enrolled) did not have data post the program. Hence, only their data at baseline were 
available to use for analysis.  Our total sample size was 714 patients. 
4.3 Measurements  
The study had 2  dependent variables (outcomes) (a) adherence [defined as 
attending more than or equal to the median number of CR sessions attended by the 
entire cohort], (b) change in cardiac risk factors (blood pressure, cholesterol, LDL, 
HDL, and BMI), which defined as the difference between post to pre values of a clinical 
factor. Baseline values of these factors were measured at the start of the program and 
at the program discharge. Therefore, patients were followed up from the start of the 
program to program completion, when they have a formal re-assessment for discharged. 
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The independent variables for our first outcome, adherence, were patient factors 
that have been documented in the literature to affect adherence to CR. These variables 
included: age; gender (male, female); nationality (Qatari, non-Qatari); tobacco use 
(smoker, non-smoker); American Association of Cardiovascular Pulmonary 
Rehabilitation (AACVPR) risk category (low, moderate, high); history of depression 
defined as[ not depressed, mild-moderate depression, severe depression], CR 
indications including heart failure (HF), angina, valve replacement (VR), valve disease, 
AMI, CAD, CABG, and PCI; comorbid conditions: diabetes mellitus, hypertension, 
back pain, and musculoskeletal disease; and  cardiac risk factors: HDL, LDL, 
cholesterol, SBP, and BMI.  
The independent variables for our third outcome, which is the change in cardiac 
risk factors after completion of the program, was adherence, i.e., attending more than 
or equal to the median number of CR sessions [median number =22] (Table 1 We also 
examined the effect of adherence to the program on change of risk factors in terms of 
number of sessions attended as a count variable. 
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Table 1 Study Dependent (Outcome) and Independent Variables 
Dependent (Outcome) 
variables 
Independent variables 
 
1. Adherence (Yes, 
No) 
[Attending ≥ 
median number of 
CR sessions 
attended which 
was 22] 
  
• Age  
• Gender 
• Nationality  
• Smoking (Yes, No)  
• History of depression (Not depressed, mild-
moderate depression, severe depression) 
• Exercise capacity (MET)  
• Comorbidities [diabetes (Yes, No), HTN 
(Yes, No), back pain (Yes, No), 
musculoskeletal disease (Yes, No)] 
• Indications: heart failure (HF), angina, 
percutaneous coronary intervention (PCI), 
coronary artery bypass grafting (CABG), 
valve disease valve replacement (VR), acute 
myocardial infarction (AMI), and coronary 
artery disease (CAD)] 
Change in cardiac risk 
factors pre-post CR  
(Cholesterol, LDL, HDL, 
and BMI) 
• Variable of interest: Adherence [Attending 
more than or equal to the median number of 
sessions] 
• Variable of interest: Number of CR sessions 
attended 
 
 
 
 
 
4.3.1 Defining cut off value for adherence 
Prior to justification of using a cut off value of the median number of sessions, 
it is essential to underline that there  is no standard definition for adherence-in terms of 
number of sessions attended- to CR programs worldwide due to the wide variation in 
length of program (duration) and the number of sessions taken by patients. Thus, 
different studies that investigated adherence used the median number of sessions of 
their own cohort as a cut off value since patients can attend a range of sessions, ideally 
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36 sessions in North America or more depending on patient condition and whether CR 
services are  covered  by a health insurance company (8). Identifying the cut off value 
in our study was solely based on similar approach used by these published studies (10, 
32, 41, 42). Hence, we followed the same approach and identified the cut off value 
based on the median number of CR sessions attended by the entire cohort of patients in 
our study. Interestingly, the median number of sessions of our study (22 sessions) was 
comparable to those in literature, i.e. 21- 26 sessions (10, 32, 41, 42). Hence, we 
followed what found in literature and we choose the median number of sessions from 
our own cohort as other studies did. 
It is important to clarify that number of sessions taken by patients is not related 
to patient risk level. Stratifying patients into low, moderate, and high risk is based on 
certain criteria (Appendix D) to assess patient safety while exercising. For example, CR 
staff prescribe the appropriate exercise intensity for each individual based on patient's 
level of risk, and for this purpose cardiac risk stratification is critical to patient safety. 
Cardiac risk stratification is used to assess patient safety before enrolment in the 
program, i.e. it is employed to predict complications during exercise. (29). It mainly 
assesses the probability of the occurrence of  "cardiac arrest" as a criterion to decide if 
a patient is at high risk for cardiac events during exercise (29) 
4.3.2 American Association of Cardiovascular Pulmonary Rehabilitation 
(AACVPR) risk category. 
A key element of exercise safety is stratification of patients according to risk 
for acute cardiovascular complications during exercise. There are different methods 
used for risk stratification, the one used in CR program in Qatar is called AACVPR risk 
category, which classifies the risk of cardiac events during exercise into [Low, 
  
 
21 
 
moderate, and high risk]. Classification of risk is based on specific criteria attached in 
(Appendix D). According to guidelines and protocols, it is necessary to prescribe the 
appropriate exercise intensity for patients so they can be able to obtain the beneficial 
effects of the program while ensuring safety during physical exercises.  
Cardiac risk stratification means careful evaluation of the clinical and functional 
status of the patient, starting with clinical history and physical, laboratory and ancillary 
tests. This procedure provides indications for the appropriate targeting of the patient 
throughout the rehabilitation process and the extent of direct staff supervision while 
exercising.  
Therefore, the identification of risk level is an integral part of the management of 
patients. For individuals classified as low risk for participating in exercise, the guideline 
recommends that direct supervision of the exercise should occur for at least 30 days 
post cardiac event or 6-18 sessions. For those with moderate risk, direct supervision 
should occur for at least 60 days post cardiac event or 12 to 24 sessions and high-risk 
patients should be monitored for at least 90 days or 18 to 36 exercise sessions. 
4.3.3 Cardiac depression scale 
In our study, we had depression in terms of scores. Thus, for the purpose of the 
analysis, we categorized the scale to 3 categories (not depressed, mild-moderate 
depression, severe depression) based on the cut off value found in the literature(43). 
Patients with depression score less than 90 were considered not depressed, 90-<100 
were considered mild-moderate depression, ≥100 considered with severe 
depression(43). This scale was validated to be used in research.  
A study conducted to validate CDS scales in UK population. The CDS scale 
was mailed to 487 individuals with coronary heart disease who were recruited from 
cardiac rehabilitation support group. Then, the process was repeated on subsample of 
  
 
22 
 
80 participants four-six weeks later for the purpose of test-retest analysis. Response rate 
was 81% and the test retest sample 54% response rate. The Factor analysis revealed a 
one‐factor solution with a high internal reliability (Cronbach's α = 0.93) and an 
acceptable test‐retest reliability (0.79). The study concluded that, CDS is both a reliable 
and sensitive instrument for measuring depression in cardiac patients and that using 
CDS  will be an excellent measure for studies of outcome in cardiac patients (44).  
Additionally, wise and colleagues reported the reliability and validity  of CDS cut of 
scores in which a cut off >100 indicate severe depression with 88% sensitivity and 84% 
specificity, score of 90 indicate mild-moderate depression with 84%  sensitivity 78% 
specificity (43) 
4.3.4 Metabolic equivalent task  (MET)   
Exercise capacity is assessed by different exercise tests [treadmill Bruce 
(METs), cycle ergometer (Watts), cardiopulmonary exercise test (VO2PEAK), 6-min 
walk test (meters)] (26). In this study MET was the used test for patients. MET is 
identified as “The maximum ability of the cardiovascular system to deliver oxygen to 
exercising skeletal muscle and of the exercising muscle to extract oxygen from the 
blood, the oxygen expenditure at rest (> 3.5 mL/min/kg body weight)” (45). 
Additionally, MET has different levels that is associated with the level of activity 
patients can tolerate. For example, patients with a MET level of 6.5 can do exercise 
without a limit while patient with 1.5 MET will be unable to carry out activities without 
discomfort. These levels are used as a reference point during cardiac rehabilitation. 
Patients who have had a heart attack or who have undergone open heart surgery are 
assisted to gradually return to normal activity levels, using MET levels as a guide to 
ensure that activity does not exceed what the patient’s heart can tolerate (46). More 
information about MET is attached in the (Appendix E). 
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4.4 Statistical analysis   
Prior to analyzing this dataset, various methods were employed to check for any 
potential errors in the data. Missing values for each variable were also assessed. The 
only two variables that had missing data were, Cardiac depression scale (4% missing) 
and Musckelotal disease (4% missing). Thus, no data imputation were needed.In order 
to prepare data for analysis, data were cleaned and coded using STATA software. To 
achieve the first study objective, measure the proportion and describe the characteristics 
of patients who adhered to the CR program, descriptive analyses were performed and 
presented as percentages for categorical variables, or means and standard deviations for 
continuous variables. The variables used in the study are shown in Table 2.  
For the second objective, to investigate patient factors associated with 
adherence, a logistic regression analysis was performed. initially, the purposeful 
selection method was followed. First, univariate analysis was conducted to detect 
variables in our data that were potentially associated with the outcome. For categorical 
variables with more than two levels, Wald statistics p-values were used to assess overall 
significance. The following independent variables were used separately to predict the 
odd of adherence in the univariate logistic regression analysis: age, gender, nationality, 
tobacco smoking, AACVPR risk category, patients indications  (PCI, CABG, CAD, 
AMI, valvular replacement), comorbidities including depression, diabetes, HTN, and 
back pain exercise capacity (MET), BMI, SBP, cholesterol, LDL, and HDL. Each of 
these variables were tested one at a time against the outcome (adherence).  
Second, clinically significant well-established variables in the literature and those 
with a p-value < 0.25 produced by the univariate analysis were included in the initial 
full model. Using p-value of 0.25 was important as a more traditional levels such as 
0.05 can fail in identifying variables known to be important.(47). Excluded variables 
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were gender, BMI, LDL, depression, AMI, heart failure, valve replacement, angina, 
valve disease, and HTN. After removing these variables, we obtained our “initial full” 
model.  
After including all variables with p-values less than 0.25[first step] in a full model, 
we conducted the regression analysis and dropped all variables with p-values greater 
than .05 (p>0.05). The only variables that remained in our model were risk level, PCI, 
CABG, musculoskeletal disease, and this formed the simpler model. To indicate which 
model is the best to predict adherence factors, a likelihood ratio test was used to decide 
whether the full model or the simpler model is a better fit. The likelihood ratio 
(LR)=11.41, had p-value=0.32 indicating that the simple model is a better fit. Hence, 
we kept the simpler model and proceeded the analysis with it.   
The third step was to adjust for confounders by using Δβ equation in which any of 
the remaining covariates who got a change (Δβ>20%) were brought back to the model 
and removed one by one to see their confounding effect. Since the remaining covariate 
all had a change <20% and no change were spotted when we brought back covariate 
one at a time that was discarded from the univariate model, we kept our simpler model, 
which included risk level, PCI, CABG, and musculoskeletal disease. Age and gender 
are well known potential confounder we brought them back in our final adjusted model. 
To achieve the third objective, to examine the relationship between number of 
sessions attended and change in cardiac risk factors (Cholesterol, LDL, HDL, and 
BMI), a multiple linear regression was conducted. First, we presented univariate 
analysis (unadjusted model) then we started to adjust for patients’ variables that is well 
known in literature to be associated with the outcome. By doing this we were able to 
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examine the difference in each model and whether adjusting for certain variables will 
affect the change in the outcome. 4 models were presented for each risk factor and we 
calculated % change in coefficient to easily notice the change in each adjusted model 
compared to the unadjusted one. (Change= β in the unadjusted model-β in new model), 
(%change= change÷ β in the unadjusted modelx100). Any variable added and had a 
change of 20% or more is considered a confounder.  
To achieve the fourth and final objective of this study,  to explore the relationship 
between number of sessions attended and the mean change in cardiac risk factors (SBP, 
cholesterol, LDL, HDL, and BMI) from pre to post CR program), for each of the 
outcome variable, we determined apriori the independent variables (from literature and 
those of clinical importance that affect each outcome). Then, we conducted a simple 
linear regression (unadjusted model) to identify the association between the change of 
each of these risk factors and number of sessions attended independently. Then, we 
conducted multiple linear regression analyses (several adjusted models), where other 
clinical and demographic independent variables were added one by one to the initial 
unadjust model. 
Additionally, a paired sample t-test was performed[dependent t-test] for each 
clinical measure. All assumptions were tested before running the test. These 
assumptions included: the dependent variable was continuous, and the outcome was 
normally distributed.  
Once we found the mean change (post clinical measure value minus pre-clinical 
measure value) for each of the clinical measures, we tested the mean difference between 
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groups (adherence, non-adherence) using an independent sample t-test. All statistical 
analysis was performed using STATA software version 16.  
 
 
 
 
Table 2 Types Of Study Variables 
 
Types of variable  Variables included in the study  
 
 
 
Continuous 
Variables  
Age (years) 
Exercise capacity (MET)  
Systolic blood pressure (SBP) mmol/L 
Body mass index (BMI) Kg/m2 
Cholesterol (mmol/L) 
Low-density lipoprotein (LDL) 
High-density lipoprotein (HDL) 
Exercise capacity (MET) 
 
 
 
Categorical 
variables  
Gender (Male, Female) 
Nationality (Qatari, Non-Qatari) 
Smoking status 
History of depression (not depressed, mild-moderate, severe 
depression) 
AACVPR risk category (low, moderate, high) 
CR indications [PCI, CABG, CAD, AMI, angina, valve 
disease, valve replacement, and heart failure]  
Comorbidities [diabetes mellitus, hypertension, back pain, 
musculoskeletal disease] 
 
 
 
4.5 Ethical Approval 
The study was approved by IRB at Hamad Medical Corporation [MRC-01-18-430] 
Heart Hospital and Institutional Review Committee from Qatar university [QU-IRB 
1039-E/19] 
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4.6 Research Significance and Implications   
Cardiac rehabilitation is a cost-effective model of care shown to reduce cardiovascular 
mortality and morbidity by 20%(9). Based on an existing meta-analysis, participation 
in a cardiac rehabilitation program reduces risk factors of CVD and decreases mortality 
and morbidity of the disease(10, 31). However, despite all the benefits documented, 
cardiac rehabilitation is still underutilized, and the adherence rate is meager (12). 
Considering CR in Qatar, there is only one qualitative study that explored reasons for 
nonattendance to the CR program without identifying what the possible factors 
associated to adhere to the program, or what are the factors associated with enrollment 
(12) are. Hence, it is essential to conduct this research to investigate possible factors 
associated with enrollment and adherence to serve as a guideline for policymakers and 
program directors. This will enable them to identify where is the gab and improve 
patient adherence, which will lead to improvement in patient’s quality of life, CVD risk 
factors, and make the program tailored to patient’s needs.  
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Figure 1 Logistic regression analysis 
 
 
 
1) Univariate analysis
age, gender, nationality, tobacco smoking, 
AACVPR risk category, PCI, CABG, CAD, 
AMI, valve replacement, depression, 
diabetes, HTN, back pain, exercise capacity 
(MET), BMI, SBP, cholesterol, LDL, and 
HDL
3) Full model 
Adherance, Age, Nationality, Risk Level 
SBP, HDL, Cholestrol, excersise capacity, 
Smoking, PCI, CABG , CAD, DM, Back 
pain, and musckelotal
5) Simpler model
Adherance, Risk level, PCI, CABG, And 
musculoskeletal disease
6) Testing for confounders one at a time 
discarded from step1
7) Final simple model included; Gender, 
Age Risk Level,PCI, CABG, musckelotal
4) Removed at p-value>0.05
Age, nationality, HDL, cholestrol, excersise 
capacity, smoking, SBP,CAD, DM, and 
back pain
2) Removed if P-value>0.25
gender, BMI, LDL,  depression, AMI, heart 
failure, valve replacement, angina, valve 
disease, and HTN
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CHAPTER5: RESULTS 
 
Over the study period, 2013-2018, a total of 714 patients were referred to the CR 
program. Of whom 682 (95.5%) patients enrolled in the program, i.e., attended at least 
one session (Figure 2). This graph represents the number of those patients’ records who 
were entered in the system at the program level, there could be patients who referred 
but the CR staff did not enter as the patients did not show up at the program. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reffered (N=714)
Enrolled 
(N=682,95.5%)
Adherent 
(N=344,50.44%)
Nonadherent 
(N=338,49.5%)
Non-
Enrolled(N=32,4.5%)
Figure 2 Study Flowchart showing the number of patients who were referred, enrolled and 
adhered to the CR 
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Figure 3 Distribution of CR sessions attended by patients 
 
 
Table 3 Summary description for Number of sessions attended  
 
 
 
 
 
 
5.1 Patients Characteristics    
Table 4 shows the characteristics of patients who were referred to the CR 
program (N=714) between January 2013 and September 2018. The majority of the 
patients were males (n= 641, 89.8%) and non-Qatari (n= 596,83.5%). The mean age of 
our study population was 52.7±10.1 years (mean ± SD). About one-fourth of the 
referred patients were smokers (n=185, 25.91%). Among our cohort, 128 patients 
Mean Median Minimum Maximum 
20.5 22 5 67 
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(18.8%) were diagnosed with severe depression while 74 patients (10.9%) were 
diagnosed with mild-moderate depression.  
Further, PCI was the most common CR indication (n=442, 61.9%) among the 
study’s population. Patients diagnosed with CAD represented (41.2%) of our cohort 
and about one-fifth (n=154, 21.6%) of the patients had undergone CABG. Of the 
referred patients, 291 (40.8%) had AMI. Less than 5% of the population had the 
following CR indications: angina (n= 12, 1.7%), heart failure (n=28, 3.9%), valve 
replacement (n=28, 3.4%), and valve disease (n=24, 3.4%). 
Considering comorbidities, hypertension was the most prevalent comorbid 
condition among our patients (n= 322, 45.1%) followed by diabetes (n=301, 42.2%). 
Only 3.9% (n=28) of the patients had back pain, and 3.1% had a musculoskeletal 
disease. Means and standard deviations of baseline clinical measures were as following:  
HDL:1.30±0.94mmol/L, LDL:1.98±1.03 mmol/L, cholesterol: 3.73±1.17 mmol/L, 
BMI: 29.60±9.68 mmol/L, exercise capacity: 9.29±3.17 MET, and SBP: 128.80±17.9 
mmHg (Table 3).  
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Table 4 Sociodemographic and Clinical Characteristic of Study Population [Referred 
Patients] at Baseline (N=714) 
Patients Characteristics N (%) 
Age (years) Mean±SD 52.7±10.1 
Gender  
  Male 641(89.8) 
  Female 73(10.2) 
Nationality  
  Qatari 118(16.5) 
  Non-Qatari 596(83.5) 
Smoking  
  Smoker 185(25.9) 
  Non-smoker 529(74.1) 
History of depression*  
  Not depressed 480(67.23) 
  Mild-moderate depression 74(10.36) 
  Severe depression 128(17.93) 
AACVPR Risk Category  
  Low 208(29.1) 
  Moderate 262(36.7) 
  High 244(34.2) 
Indications  
PCI  
Yes 442(61.9) 
No 272(38.1) 
Coronary artery disease  
Yes 294(41.2) 
No 420(58.8) 
Myocardial infarction  
Yes 291(40.8) 
No 423(59.2) 
CABG  
Yes 154(21.6) 
No 560(78.4) 
Heart failure  
Yes 28(3.9) 
No 686(96.1) 
Valve replacement  
Yes 28(3.9) 
No 686(96.1) 
Valve disease  
Yes 24(3.4) 
No 690(96.6) 
AACVPR, American Association of Cardiovascular and Pulmonary Rehabilitation; PCI, Percutaneous 
Coronary Intervention 
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5.2 Patients Characteristics Associated with Adherence 
 Patient sociodemographic and clinical characteristics by adherence are 
presented in Table 5.  Patients in the adherent group were older (54.05±10.0 years) 
compared to non-adherent (51.1±9.8). The majority of adherents were males (91.0%), 
non-smokers (79.1%), and without depression (71.5%). Almost half (49.7%) of the 
adherents had moderate AACVPR risk. For indications, 58.7% of the adherents had 
PCI, 52.3% diagnosed as CAD, and 37.5% diagnosed as AMI. The adherents were less 
Patients Characteristics N (%) 
Indications  
Angina  
Yes 12(1.7) 
No 702(98.3) 
Comorbid conditions  
  HTN  
  Yes 322(45.1) 
  No 392(54.9) 
  Diabetes mellitus  
  Yes 301(42.2) 
  No 413(57.8) 
  Back pain  
  Yes 28(3.9) 
  No 686(96.1) 
  Musculoskeletal diseases*  
  Yes 21(2.9) 
  No 661(92.6) 
Clinical measures   
  Systolic blood pressure (mmHg) (Mean±SD) 128.80±17.9 
  BMI (Kg/m2) (Mean±SD) 29.60±9.68 
  Exercise capacity (MET)  9.29±3.17 
  Cholesterol (mmol/L) (Mean±SD) 3.73±1.17 
  LDL (mmol/L) (Mean±SD) 1.98±1.03 
  HDL (mmol/L) (Mean±SD) 1.30±0.94 
AACVPR, American Association of Cardiovascular and Pulmonary Rehabilitation; CR, cardiac rehabilitation. HTN, 
hypertension. LDL, low-density lipoprotein. HDL, high-density lipoprotein. PCI, Percutaneous Coronary Intervention. 
CABG, Coronary artery bypass grafting SD, standard deviation.  (%) given for categorical variables. * missing 
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likely to have angina (1.5%), heart failure (4.1%), valve replacement (4.1%), and valve 
disease (3.5%).  
 Considering the non-adherent group, PCI (70.1%), CAD (44.4%), and AMI 
(36.7%) were also the most common CR indications. With the highlight that patients 
undergoing PCI were the highest compared to adherent patients. Patients undergoing 
CABG represented only (17.2%). Angina (0.95%), heart failure (3.25%), valve 
replacement (3.55%), and valve disease (2.96%) were the least common indication 
among the non-adherent group 
 The results also showed that (44.19%) patients had diabetes among adherent 
group compared to (55.81%) nondiabetic. The non-adherent group had (36.98%) 
diabetic patients compared to (63.02%) nondiabetic. Whereas HTN patients 
represented (45.35%) in the adherent group compared to (54.65%) not hypertensive. 
The non-adherent group had (43.20%) of hypertensive patients and (56.80%) non- 
hypertensive. Back pain and musculoskeletal disease were the least common 
comorbidities among both groups. In which adhered patients with back pain represented 
(1.45%) compared to (6.21%) of non-adhered patients having back pain. As for 
musculoskeletal disease, (1.45%) of adhered patients had it compared to (5.03%) non 
adhered patients without musculoskeletal disease.   
Finally, Clinical measures at baseline were almost similar in both groups except 
for a minor difference in some of the measures. Mean HDL among adherent group was 
(1.06±0.31) compared to (1.05±1.28) among non-adherent groups. AS for LDL, non-
adherent group had slightly higher HDL mean (2.02±1.14) compared to adherent group 
LDL mean (1.95±0.93). The cholesterol level among adhered patients was (3.66±1.09) 
compared to (3.81±1.26) among non-adhered group. Adhered patients had higher SBP 
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mean (130.35±18.65) than non-adhered group (126.89±17.06). Last measure we have 
was BMI (kg/m2). Mean BMI did not differ in both groups. Adherent patients had a 
mean BMI of (29.18±5.36) compared to (28.83±5.02) in non-adherent group.  
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Table 5 Sociodemographic and Clinical Characteristic of Patients at Baseline by 
Adherence (N=682) 
Characteristics Adherent (N=344, 
50.44%) 
Nonadherent (N=338, 
49.5%) 
n (%)/ Mean±SD n (%)/ Mean±SD 
Age 54.05±10.00 51.1±9.77 
Gender 
  
Male 313(91.0) 300(88.8) 
Female 31(9.0) 38(11.2) 
Nationality 
  
Qatari 40(11.6) 65(19.2) 
Non-Qatari 304(88.4) 273(80.8) 
Smoking 
  
Smoker 72(20.9) 103(30.5) 
Non-smoker 272(79.1) 235(69.5) 
History of depression 
  
Not depressed 246(71.5) 234(69.2) 
Mild-moderate 35(10.2) 39(11.5) 
Severe 63(18.3) 65(19.2) 
AACVPR Risk 
Category 
  
Low 29(8.4) 174(51.5) 
Moderate 171(49.7) 81(24.0) 
High 144(41.9) 83(24.6) 
Indications 
  
PCI 
  
Yes 202(58.7) 237(70.1) 
No 142(41.3) 101(29.9) 
CABG 
  
  Yes 89(25.9) 58(17.2) 
  No 255(74.1) 280(82.8) 
Myocardial infarction 
  
  Yes 129(37.5) 124(36.7) 
  No 215(62.5) 214(63.3) 
Angina 
  
  Yes 5(1.4) 2(0.9) 
  No 339(98.5) 208(99.0) 
Heart failure 
  
  Yes 14(4.1) 11(3.2) 
  No 330(95.9) 327(96.7) 
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Characteristics 
 
Adherent (N=344, 
50.44%) 
 
Nonadherent (N=338, 
49.5%) 
 n (%)/ Mean±SD n (%)/ Mean±SD 
Indications    
Valve replacement   
Yes 14(4.1) 12(3.5) 
No 330(95.9) 326(96.4) 
Valve disease   
Yes 12(3.5) 10(3.0) 
No 332(96.5) 328(97.0) 
Coronary artery disease 
  
  Yes 183(53.2) 150(44.4) 
  No 161(46.8) 188(55.6) 
Comorbid conditions 
  
Diabetes mellitus 
  
  Yes 152(44.2) 125(37.0) 
  No 192(55.8) 213(63.0) 
HTN 
  
  Yes 156(45.3) 146(43.2) 
  No 188(54.6) 192(56.8) 
Back pain 
  
  Yes 5(1.45) 21(6.21) 
  No 339(98.55) 317(93.79) 
Musckelotal diseases 
  
  Yes 5(1.4) 17(5.0) 
  No 339(98.5) 321(95.0) 
Clinical measures   
HDL (mmol/L) 1.06±0.31 1.05±1.28 
LDL (mmol/L) 1.95±0.93 2.02±1.14 
Cholesterol (mmol/L) 3.66±1.09 3.81±1.26 
Systolic blood pressure 
(mmHg) 
130.35±18.65 126.89±17.06 
Exercise capacity (MET) 8.9±3.4 9.7±2.7 
Body mass index (Kg/m2) 29.18±5.36 28.83±5.02 
P-value<0.001 and 0.05 is considered significant.  OR, Odd ratio; CI, Confidence interval. AACVPR, American Association of 
Cardiovascular and Pulmonary Rehabilitation; CR, cardiac rehabilitation. HTN, hypertension. LDL, low-density lipoprotein. 
HDL, low-density lipoprotein. PCI, percutaneous coronary intervention. CABG, coronary artery bypass grafting 
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5.3 Patient characteristics associated with adherence [Univariate logistic 
regression]  
Table 6 shows the crude association between adherence and potential patient 
factors, the following factors were significantly associated with adherence: age 
(p<0.001), nationality (p=0.006), risk level (p<0.001), smoking (p=0.01), PCI 
(p<0.001), CABG (p=0.01), CAD (p=0.021), DM with borderline significant result 
(p=0.05), back pain (p<0.001), musculoskeletal disease (p=0.013), SPB (p=0.01), and 
HDL (p<0.001). Age was positively associated with adherence [OR=1.02, 95%CI= 
1.01-1.05], i.e., for every one-year increase in age, the odds of being adherent increased 
by (2%), without adjusting for other variables. Compared to Qatari, non-Qatari patients 
were 81% more likely to adhere [OR=1.81, 95%CI=1.18-2.77]. As for the risk category, 
the odd of being adhered to the CR program among the moderate-risk group 
[OR=12.67, 95%CI=7.89-20.34] was 12.67 times the odd of adhering compared to the 
low-risk group. Additionally, the odd of adhering among the high-risk group 
[OR=10.41, 95%CI=6.46-16.77] was 10.41 times the odd of adhering compared to the 
low-risk group. Further, the odd of adherence were 40% less among smokers compared 
to non-smoker patients. The results also revealed that the odd of adhering to CR 
decreased by 39% among patients with PCI indications compared to those without PCI. 
On the other hand, the odd of being adhered to the program among patients who had 
CABG increased by 68% [OR=1.68, 95%CI=1.16-2.44] compared to patients without 
CABG. Similarly, the odd of adhering to CR increased by 42% [OR=1.42, 
95%CI=1.05-1.93] in patients with CAD compared to those without CAD. 
For comorbid conditions, the odd of adhering to CR among diabetic patients increased 
by 35% [OR=1.35, 95%CI=0.99-1.83] compared to non-diabetic patients. The odd of 
adhering to CR among patients with back pain decreased by 78% [OR=0.22, 
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95%CI=0.07-0.60] compared to those without back pain, whereas the odd of adherence 
among patients with musculoskeletal disease decreased by 72% [OR=0.28, 
95%CI=0.10-0.76] compared to those without the musculoskeletal disease. The result 
also showed that for each one (mmHg) increase in SBP, the odd of adherence increased 
by 1% [OR=1.01, 95%CI=1.00-1.02]. Finally, for each one unit (mmol/L) increase in 
HDL the odd of being adherent to CR decreased by 60% [OR=0.40, 95%CI=0.29-0.54]. 
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Table 6 Univariate logistic regression analysis of Adherence (dependent variable). 
The Crude association between Adherence and potential patients’ factors. 
 
Variables OR 95%CI P-value 
Age 1.02 1.01 1.05 <0.001 
Gender     
  Female Ref    
  Male 1.28 0.78 2.11 0.34 
Nationality      
  Qatari Ref    
  Non-Qatari 1.81 1.18 2.77 0.006 
AACVPR Risk Category      
  Low risk  Ref    
  Moderate risk 12.67 7.89 20.34 <0.001 
  High risk  10.41 6.46 16.77 <0.001 
Cardiac Depression Scale (CDS)      
  No depression  Ref    
  Moderate-mild depression 0.85 0.52 1.39 0.53 
  Severe depression 0.92 0.62 1.36 0.68 
Smoking      
  No   Ref    
  Yes 0.60 0.43 0.86 0.01 
Indications     
PCI      
  No Ref    
  Yes 0.61 0.44 0.83 <0.001 
CABG     
  No Ref    
  Yes 1.68 1.16 2.44 0.01 
Coronary artery disease     
  No Ref    
  Yes 1.42 1.05 1.93 0.021 
Myocardial infarction     
  No Ref    
  Yes 1.04 0.76 1.41 0.83 
Heart failure     
  No   Ref    
  Yes 1.26 0.56 2.82 0.57 
Valve replacement     
  No Ref    
  Yes 1.15 0.53 2.53 0.72 
Angina      
  No Ref    
  Yes 1.53 0.29 7.98 0.61 
Valve disease     
  No Ref    
  Yes 1.19 0.51 2.78 0.70 
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5.4 Patient characteristics associated with adherence [Multivariable logistic 
regression]- Adjusted model 
Results of the adjusted multivariable regression model presented in Table 7. Our 
final model had three patients’ factors significantly associated with adherence, which 
were AACVPR risk (p<0.001), PCI (p=0.03), and musculoskeletal disease (p=0.05). 
Compared to patients with low AACVPR risk,  patients with moderate risk were almost 
13  times more likely to adhere [OR=12.71, 95%CI=7.81-20.68], while patients with 
high risk were almost 11 times more likely to adhere [OR=10.60, 95%CI=6.44-17.44]. 
The results of the adjusted model also showed that patients with PCI were 61% less 
likely to adhere [OR=0.39, 95%CI=0.17-0.89] compared to those without PCI.   
The same negative association was found among patients with musculoskeletal 
Variables OR 95%CI P-value 
Comorbid Conditions     
Diabetes mellitus     
  No Ref    
  Yes 1.35 0.99 1.83 0.05 
HTN     
  No Ref    
  Yes 1.09 0.81 1.48 0.57 
Back pain     
  No Ref    
  Yes 0.22 0.07 0.60 <0.001 
Musculoskeletal disease     
  No Ref    
  Yes 0.28 0.10 0.76 0.013 
Body mass index (Kg/m2) 1.01 0.98 1.04 0.381 
Systolic blood pressure (mmHg) 1.01 1.00 1.02 0.01 
LDL (mmol/L) 0.94 0.81 1.08 0.38 
HDL (mmol/L) 0.40 0.29 0.54 <0.001 
Cholesterol (mmol/L) 0.90 0.79 1.03 0.12 
P-value<0.001 and 0.05 is considered significant.  OR, Odd ratio; CI, Confidence interval. AACVPR, American 
Association of Cardiovascular and Pulmonary Rehabilitation; CR, cardiac rehabilitation. HTN, hypertension. 
LDL, low-density lipoprotein. HDL, low-density lipoprotein. PCI, percutaneous coronary intervention. CABG, 
coronary artery bypass grafting 
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disease, who were 83% [OR=0.17, 95%CI=0.03-0.95] less likely to adhere compared 
to those without musculoskeletal disease. 
Since we did not find any confounding factors to bring back in our simpler 
model, we decided to bring clinical variables that shown to be well-known confounders 
from literature, and these are age and gender even though they were not statistically 
significant. Results of the final model, with confounders, are presented in Table 8. 
 
Table 7 Multivariable Logistic Regression to Determine Predictors of Adherence 
(Adjusted Association) 
Variables AOR 95%CI P-value 
Age (years) 1.01 0.98 1.04 0.42 
Gender     
  Female Ref    
  Male 1.20 0.53 2.74 0.66 
AACVPR Risk Category     
  Low risk Ref    
  Moderate risk 12.71 7.81 20.68 <0.001 
  High risk 10.60 6.44 17.44 <0.001 
PCI     
  No Ref    
  Yes 0.39 0.17 0.89 0.03 
CABG     
  No Ref    
  Yes 0.49 0.19 1.28 0.14 
Musculoskeletal diseases     
  No Ref    
  Yes 0.15 0.06 0.5 0.003 
P-value<0.05 is significant.  AACVPR, American Association of Cardiovascular and Pulmonary Rehabilitation. PCI, 
percutaneous coronary intervention; CABG, coronary artery bypass grafting 
 
 
 
 
 
 
 
 
  
 
43 
 
5.5 Adherence association with change in risk factors from pre to post CR 
program 
Initially, a paired t-test was run to determine whether there was a statistically 
significant mean difference between patients’ clinical measures before and after the 
program (3 months follow up) in both groups separately [adherence and non-adherence. 
As shown in table 8, there was a statistically significant mean difference for all clinical 
measures, including BMI, LDL, HDL, cholesterol, and SBP (p-value <0.001, for all). 
The mean SBP had the most significant change from pre to post CR 
program,130.35±18.65 to 124.98±15.81, respectively, among the adhered group.  
Table 10 shows the change in measures between adherents and non-adherents 
in addition to the total mean difference between groups. The result revealed that the 
mean difference between groups were BMI (-0.34, 95%CI= -1.113-0.44), HDL (-
0.004,95%CI= -0.65-0.05), LDL (0.008, 95%CI= -0.14-0.16) and SBP (-1.62, 95%CI= 
-4.37-1.11). Additionally, the independent samples t-test results revealed that there was 
no statistically significant difference in the means though there was a mean change pre 
and post the program.  
Table 8 and 9 demonstrates the change and percentage of change in clinical 
measures among the adherent and non adherent group afte program completion. The 
result showed improvements in all measures. Specifically, there was a 10% reduction 
in total cholesterol level [95%CI= -0.31- -0.50] and a 15% reduction in LDL level 
[95%CI= -0.22- -0.40]. Among non adherent group, A 16% reduction was found  in 
LDL level level [95%CI= -0.19- -0.44] , compared to adherent group it is is considered 
better reduction eventhough  it’s a reduction difference  by 1% only.
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Table 8  Change in Clinical Measures Among Adherent group 
Measures  Adherence 
 
Pre Post Mean Difference 95% CI P-value % change 
BMI (Kg/m2) 29.18±5.36 27.63± 5.23 -0.54±2.40 -0.29 -0.80 <0.001 -1.8% 
LDL (mmol/L) 1.95±0.93 1.26±0.78 -0.31±0.86 -0.22 -0.40 <0.001 -15% 
HDL (mmol/L) 1.06±0.31 0.92± 0.29 -0.13±0.26 -0.10 -0.16 <0.001 -12% 
Cholesterol(mmol/L) 3.66±1.09 3.26±0.74 -0.40±0.89 -0.31 -0.50 <0.001 -10% 
SBP (mm Hg) 130.35±18.65 124.98±15.81 -5.36±17.33 -3.53 -7.20 <0.001 -4% 
Values are expressed as mean ± standard deviation. P-value<0.05 is significant. BMI, body mass index; LDL, low-density lipoprotein; HDL, high-density lipoprotein; SBP, systolic blood pressure; 95%CI= 
confidence interval  
 
 
Table 9 Change in Clinical Measures Among Adherent group 
Measures  Non-adherence 
 
Pre Post Mean difference 95% CI P-value % change 
BMI (Kg/m2) 28.07±5.03 27.62±5.23 -0.44±2.09 -0.16 -0.73 0.002 -1.5% 
LDL (mmol/L) 1.95±1.02 1.63± 1.51 -0.32±0.93 -0.19 -0.44 <0.001 -16% 
HDL (mmol/L) 1.03±0.44 0.90± 0.32 -0.13±0.44 -0.06 -0.19 <0.001 -12% 
Cholesterol(mmol/L) 3.62± 1.25 3.28±0.92 -0.33±0.96 -0.20 -0.47 <0.001 -9.1% 
SBP (mm Hg) 125.4± 15.85 121.7± 12.90 -3.74±13.41 -1.91 -5.56 <0.001 -2.9% 
Values are expressed as mean ± standard deviation. P-value<0.05 is significant. BMI, body mass index; LDL, low-density lipoprotein; HDL, high-density lipoprotein; SBP, systolic blood pressure 
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Table 10 Mean Change between Adherent and Non-adherent group 
Measure Mean difference between groups 95%CI P-value 
BMI (Kg/m2) -0.34 -1.13 0.433 0.38 
LDL (mmol/L) 0.008 -0.14 0.16 0.90 
HDL (mmol/L) -0.004 -0.65 0.05 0.89 
Cholesterol(mmol/L) 0.03 -0.12 0.19 0.68 
SBP (mm Hg) -1.62 -4.37 1.11 0.24 
Values are expressed as mean ± standard deviation. P-value<0.05 is significant. BMI, body mass index; LDL, low-density lipoprotein; HDL, high-density lipoprotein; SBP, systolic blood pressure; 95%CI= confidence 
interval 
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5.6 CVD risk factors and its association with number of sessions attended in CR 
program  
Table 11 shows the association between change in BMI (outcome) and patient 
factors. the unadjusted BMI model (univariate model) had a β coefficients of (β 
=0.0027). When adjusting for age, this led to a reduction of 55.5% in β coefficients and 
it became (β=0.0012). We then adjusted for gender(β=0.0016) that showed a reduction 
of 40.7%, then we added risk level to adjust for in our model we noticed a reduction of 
174 in beta coefficients (β=-0.0020), PCI ahd a reduction of 170 and the coefficient was 
(β=-0.0019), when adjusting for CABG(β=-0.0039) we had a reduction of 244 
compared to the unadjusted model, diabetes(β=-0.0053) with a reduction of269, when 
adjusting for Musckelotal disease the coefficients did not change (β=-0.0053). we then 
adjusted for CAD that showed a reduction of 274 in the coefficients (β=-0.0047), and 
finally we adjusted for smoking and the β coefficients was (β=-0.005) with a reduction 
of 285. All of these 11 models we have in table 11 had a very low R2 which mean the 
explanatory variables does not explain the variability in the outcome.  
Table 12 shows the association between cholesterol and main explanatory 
variable (number of sessions) adjusting for well-known variables to compare the change 
in each model. Compared to the unadjusted model(β=-0.0064), multiple model 
adjusting for age showed a reduction in beta coefficient by -4.7(β=-0.0067) adjusting 
for more variables, R2 increased somehow however the increase was not that huge as 
the model explanatory variable did not explain the variability in the outcome (only 1% 
is explained). We then kept on adding more variables that were reported in literature to 
be associated with the outcome. Thus, we adjusted for risk level (β=-0.0083, -29.6 
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reduction), PCI(β=-0.0081, -26.56), CABG(-0.0084, -31.25 reduction compared to 
unadjusted model), Musckelotal disease (β=-0.0088, -37.5 reduction), Smoking(β=-
0.0078, -21.8 reduction), and when adjusting for diabetes and CAD same reduction was 
experience in beta coefficient (β=-0.009, -40.6 reduction).  
Table 13 and 14 shows the results of our last two outcomes high density 
lipoprotein (HDL) and low density lipoprotein (LDL) against the number of attended 
sessions adjusting for patients factors one at a time. In HDL when adjusting for age and 
gender they had the same effect as beta coefficients did not change much (β=-0.0017) 
compared to the unadjusted model. we kept adding to the model without having extreme 
changes in beta coefficient until the final multiple model were, we had (β=-0.007, -53.3 
reduction) after adding CAD variable. As for LDL, the highest beta coefficient 
reduction was explained when adding CAD variable in which (β=-0.0052, -29.03 
reduction) compared to unadjusted model that had a (β=-0.0074).   
Even though we are adding more variable to our four models, still we can notice 
R2 to be very low which could be explained that other important variables not included 
in our study is needed to explain the variability in the outcome. Additionally, all of the 
models did not have any statistically significant change in CVD.  
 
 
 
 
  
 
48 
 
Table 11 Association of Number of Sessions Attended  with Chamge in BMI (adjusted and unadjusted models) 
 
 
 
BMI β β % 
change 
95%CI P-
value 
R2 
Main model (BMI+ Number of attended sessions) 
0.0027 
N/A 
-0.0202 0.0257 0.8160 0.0001 
BMI+ Number of attended sessions+ Age   0.0012 55.5 -0.0222 0.0246 0.9210 0.0009 
BMI + Number of attended sessions + Age + Gender   0.0016 40.7 -0.0219 0.0250 0.8960 0.0039 
BMI+ Number of  attended  sessions + Age +Gender +Nationality    0.0014 48.1 -0.0220 0.0248 0.9070 0.0045 
BMI +Number of  attended  sessions +Age +Gender+ Nationality+ Risk level   -0.0020 174 -0.0348 0.0309 0.9070 0.0046 
BMI+ Number of  attended  sessions+ Age+ Gender +Nationality +Risk level+ 
PCI  -0.0019 
170 
-0.0348 0.0310 0.9090 0.0046 
BMI+ Number of  attended sessions+ Age +Gender +Nationality +Risk level+ 
PCI+ CABG  -0.0039 
244 
-0.0368 0.0291 0.8180 0.0105 
BMI+ Number of  attended  sessions+ Age+ Gender+ Nationality+ Risk level+ 
PCI+ CABG+ Musckelotal diseases  -0.0053 
269.3 
-0.0383 0.0278 0.7550 0.0122 
BMI+ Number of  attended sessions+ Age+ Gender+ Nationality +Risk level+ 
PCI+ CABG+ Musckelotal diseases+ Diabetes   -0.0053 
269.3 
-0.0384 0.0278 0.7550 0.0122 
BMI+ Number of  attended sessions+ Age+ Gender+ Nationality+ Risk level+ 
PCI+ CABG+ Musckelotal diseases+ Diabetes +CAD   -0.0047 
274 
-0.0380 0.0286 0.7810 0.0124 
BMI+ Number of  attended sessions+ Age+ Gender+ Nationality+ Risk level+ 
PCI+ CABG+ Musckelotal diseases+ Diabetes+ CAD+ Smoking     -0.0050 
285 
-0.0384 0.0284 0.7690 0.0125 
*PCI; Percutaneous Coronary Intervention CABG; Coronary artery bypass grafting, CAD; Coronary artery disease 
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Table 12 Association of Number of Sessions Attended  with Chamge in Cholesterol (adjusted and unadjusted models) 
 
 
Cholesterol β β % change 95%CI P-
value  
R2 
Cholesterol + Number of attended sessions  -0.0064 N/A -0.0156 0.0028 0.1750 0.0033 
Cholesterol + Number of attended sessions+ Age   -0.0067 -4.7 -0.0161 0.0027 0.1640 0.0035 
Cholesterol + Number of attended sessions + Age + Gender   -0.0068 -6.3 -0.0162 0.0026 0.1560 0.0062 
Cholesterol + Number of attended sessions + Age +Gender +Nationality    -0.0069 -7.8 -0.0163 0.0025 0.1490 0.0084 
Cholesterol +Number of attended sessions +Age +Gender+ Nationality+ Risk 
level   -0.0083 
-29.6 
-0.0215 0.0049 0.2160 0.0101 
Cholesterol + Number of attended sessions+ Age+ Gender +Nationality +Risk 
level+ PCI  -0.0081 
-26.56 
-0.0213 0.0051 0.2280 0.0112 
Cholesterol + Number of attended sessions+ Age +Gender +Nationality +Risk 
level+ PCI+ CABG  -0.0084 
-31.25 
-0.0217 0.0048 0.2100 0.0123 
Cholesterol + Number of attended sessions+ Age+ Gender+ Nationality+ Risk 
level+ PCI+ CABG+ Musckelotal diseases  -0.0088 
-37.5% 
-0.0221 0.0045 0.1930 0.0131 
Cholesterol + Number of attended sessions+ Age+ Gender+ Nationality +Risk 
level+ PCI+ CABG+ Musckelotal diseases+ Diabetes   -0.0090 
-40.6 
-0.0223 0.0042 0.1820 0.0153 
Cholesterol + Number of attended sessions+ Age+ Gender+ Nationality+ Risk 
level+ PCI+ CABG+ Musckelotal diseases+ Diabetes +CAD   -0.0080 
-40.6 
-0.0214 0.0053 0.2390 0.0189 
Cholesterol + Number of attended sessions+ Age+ Gender+ Nationality+ Risk 
level+ PCI+ CABG+ Musckelotal diseases+ Diabetes+ CAD+ Smoking   -0.0078 
-21.8 
-0.0212 0.0056 0.2520 0.0193 
*PCI; Percutaneous Coronary Intervention CABG; Coronary artery bypass grafting, CAD; Coronary artery disease 
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Table 13 Association of Number of Sessions Attended  with Chamge in HDL (adjusted and unadjusted models) 
 
 
 
 
HDL β β % change 95%CI P-value R2 
HDL + Number of attended sessions  -0.0015 N/A -0.0051 0.0020 0.3990 0.0013 
HDL + Number of attended sessions+ Age   -0.0017 -13.33 -0.0054 0.0019 0.3560 0.0017 
HDL + Number of attended sessions + Age + Gender   -0.0017 -13.33 -0.0053 0.0020 0.3630 0.0023 
HDL + Number of attended sessions + Age +Gender +Nationality    -0.0018 -20 -0.0054 0.0019 0.3470 0.0058 
HDL +Number of attended sessions +Age +Gender+ Nationality+ Risk level   -0.0011 -26.6 -0.0062 0.0040 0.6810 0.0094 
HDL + Number of attended sessions+ Age+ Gender +Nationality +Risk 
level+ PCI  
-0.0011 -26.6 -0.0062 0.0040 0.6720 0.0096 
HDL + Number of attended sessions+ Age +Gender +Nationality +Risk 
level+ PCI+ CABG  
-0.0010 -33.3 -0.0061 0.0042 0.7140 0.0110 
HDL + Number of attended sessions+ Age+ Gender+ Nationality+ Risk 
level+ PCI+ CABG+ Musckelotal diseases  
-0.0011 -26.67 -0.0062 0.0041 0.6880 0.0114 
HDL + Number of attended sessions+ Age+ Gender+ Nationality +Risk 
level+ PCI+ CABG+ Musckelotal diseases+ Diabetes   
-0.0011 -26.67 -0.0063 0.0041 0.6720 0.0122 
HDL + Number of attended sessions+ Age+ Gender+ Nationality+ Risk 
level+ PCI+ CABG+ Musckelotal diseases+ Diabetes +CAD   
-0.0007 -53.3 -0.0059 0.0044 0.7790 0.0153 
HDL + Number of attended sessions+ Age+ Gender+ Nationality+ Risk 
level+ PCI+ CABG+ Musckelotal diseases+ Diabetes+ CAD+ Smoking   
-0.0008 -46.6 -0.0060 0.0044 0.7510 0.0160 
*HDL; high density lipoprotein PCI; Percutaneous Coronary Intervention CABG; Coronary artery bypass grafting, CAD; Coronary artery disease 
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Table 14 Association of Number of Sessions Attended  with Chamge in LDL (adjusted and unadjusted models) 
 
LDL β β % change 95%CI P-value R2 
LDL + Number of attended sessions  -0.0074 N/A -0.0163 0.0015 0.1040 0.0048 
LDL + Number of attended sessions+ Age   -0.0075 -1.35 -0.0166 0.0016 0.1060 0.0048 
LDL + Number of attended sessions + Age + Gender   -0.0075 -1.35 -0.0166 0.0016 0.1080 0.0049 
LDL + Number of attended sessions + Age +Gender +Nationality    -0.0076 -2.7 -0.0167 0.0015 0.1010 0.0083 
LDL +Number of attended sessions +Age +Gender+ Nationality+ Risk level   -0.0084 -13.51 -0.0211 0.0043 0.1930 0.0171 
LDL + Number of attended sessions+ Age+ Gender +Nationality +Risk 
level+ PCI  -0.0083 
-12.16 
-0.0210 0.0044 0.2000 0.0175 
LDL + Number of attended sessions+ Age +Gender +Nationality +Risk 
level+ PCI+ CABG  -0.0078 
-5.41 
-0.0206 0.0049 0.2290 0.0201 
LDL + Number of attended sessions+ Age+ Gender+ Nationality+ Risk 
level+ PCI+ CABG+ Musckelotal diseases  -0.0077 
-4.05 
-0.0205 0.0051 0.2390 0.0202 
LDL + Number of attended sessions+ Age+ Gender+ Nationality +Risk 
level+ PCI+ CABG+ Musckelotal diseases+ Diabetes   -0.0076 
-2.7 
-0.0204 0.0053 0.2480 0.0210 
LDL + Number of attended sessions+ Age+ Gender+ Nationality+ Risk 
level+ PCI+ CABG+ Musckelotal diseases+ Diabetes +CAD   -0.0052 
-29.7 
-0.0180 0.0076 0.4220 0.0406 
LDL + Number of attended sessions+ Age+ Gender+ Nationality+ Risk 
level+ PCI+ CABG+ Musckelotal diseases+ Diabetes+ CAD+ Smoking   -0.0054 
-27.03 
-0.0182 0.0074 0.4070 0.0410 
*LDL; low density lipoprotein PCI; Percutaneous Coronary Intervention CABG; Coronary artery bypass grafting, CAD; Coronary artery disease 
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CHAPTER 6: DISCUSSION 
6.1 Patient adherence  
The present study examined patients’ factors associated with adherence to cardiac 
rehabilitation program and change in cardiac risk factors. Findings concerning patient 
factors associated with adherence to CR program were aligned with other published 
studies and literature. To the best of our knowledge, this is the first study that 
investigated patients’ factors associated with enrollment and adherence in Qatar. 
Variations in adherence rate could be due to different definitions of adherence as 
there is no standard definition in terms of the number of sessions attended by the 
patients. However, the median number of sessions has been used in literature for patient 
adherence(32). The median number of sessions (22 sessions) attended by our cohort is 
comparable to the median number of 21, and 25 sessions attended in published studies 
in the USA, where a standard program consists of 36 exercise sessions(10, 31, 32). 
Additionally, the program in Qatar follows the North American guidelines with 36 
sessions for program completion. 
Patients factors found to be positively associated with adherence were age, 
nationality, risk level, being diabetic, undergoing CABG procedure, and having 
coronary artery disease. These factors were consistent with other patients factors 
associated with adherence and reported in other studies findings(32, 34, 48).  
Our finidings revealed that only 11% of Qatari adhered to the program compared 
to 89% non Qatrai. This high variation between Qatari and non Qatari might be 
explained due to the fact that Qatri have portable health insurance that they can seek 
treatment outside the country, i.e. the insurance company covers most of the  expenses. 
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Adding to this and based on the insight of one health care providers working in 
governmental hospoital in Qatar, he stated that in general, Qatari patients do not adher 
to their appointments or services provided by the healthcare system because of delays 
in the appointnments or any services provideded. Moreover, the change in their 
physiscians they used to follow up may play a role of nonadherence. For example a 
ptient will follow up with a consultant and when he comes for the next follow up 
appointment he will be surprised to see another physiscan (specialist or resident 
physisans). He also added that waiting list fo certin procedures is a huge issue for 
Qatari, especially for at-high risk patients. Since these patients know their risk 
conditions, they are worried and  don’t wait rather they travel abroad, where they do a 
full assesment and seek treatment for the condition. Finally, some Qatari patients who 
travel abroad think that outside health services is better but it is not necessirealy the 
case. Peninsula one of the most well known electronic newspaper in Qatar, reported 
that, despite huge investments in healthcare, a growing number of Qataris are seeking 
treatment abroad, costing the government $329.6 million (QR1.2bn) in 2012 – which 
is more than double what it spent two years ago (49). We believe that research is needed 
for a better understanding of why Qatari travel abroad for treatment.  The 
aforementioned suggested explanation was based on personal experience of a 
healthcare provider not a well established research.  
Regarding predictors of adherence, most studies found combinations of variables 
to be related (32, 36, 48, 50). Patient factors that were negatively associated with 
adherence in our study included PCI and musculoskeletal disease. These findings are 
consistent with other studies(48, 50). The reason PCI might be negatively associated 
with adhereance could be due to the fact that the majority of PCI patients in our study 
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are of low risk. And based on literature, they might perceive themselves as not a risk 
group thus no need for them to take exercise sessions under supervision of CR staff so 
they most likely continue exercising at home(51). Wherase for patients with 
musckelotal diseases, they do not adhere to CR program as they are mostly not advised 
to enter CR due to thecomplication. Having musckelotal diseases limit the ability to do 
moderate exercise. Additionally, a low CR adherance rate is expected in patients with 
pain and those with movement difficulty, but this depends on the degree of pain and 
severity of movement difficulty that our patients could have more severe conditions. 
Thus, it may be the reason for being negatively associated with adherence (52).  
Further, in our final predicted model for adherence, the risk category was a strong 
predictor for adherence. This finding is supported by other studies (32). In general, 
patients with higher risk levels, are prescribed more number of sessions to assist them 
towards recovering their cardiac health as well as resuming their regular daily activities.  
However, the odds ratio for both risk levels was large with a wide range of confidence 
intervals, which indicates large variability in these predictors.  
A plausible reason could be the large variation in the number of sessions attended 
by the high-risk patients; some patients attended sessions up to 67 sessions which is 
more than the maximum range found in literature which is 36 sessions. Looking at our 
data, the range of attended sessions among the high-risk group was [5 to 67] sessions, 
moderate risk group ranged between [5 to 40] sessions, and low-risk group [5 to35] 
session as patients in the program were allowed to take more than the prescribed session 
as long as it is safe to remove the electrocardiography (ECG) monitoring during 
exercise. Importantly, the program was free regardless of the number of sessions 
attended by patients, which may have an essential role in attending more sessions, 
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especially among patients who did not have a job or retired. 
6.2 Change in CVD risk factors 
Our study showed a significant mean change for each of the patient's clinical 
measures pre-post the program, including body mass index, systolic blood pressure, 
LDL, HDL, and cholesterol. These results are similar to findings of other studies (38, 
53) to CR. The paired t-test showed a significant difference in cardiac risk factors 
among the non-adherent group as well.  
We ended up having equal reduction in both groups which further confirm 
adherence does not play a role in this reduction. This could be due to the lack of critical 
patient data in our study affecting adherence e.g., social support, educational level, 
transportation, employment, marital status, family support, and medication. More 
informative results on factors associated with adherence would be revealed if these 
variables been involved.  
Additionally, the independent samples t-test results revealed that the association 
between adherence, attending at least 22 sessions, and the mean change for each of the 
clinical measure was not statistically significant, i.e., attending more sessions was not 
a predictor for the change in any of these clinical measures: cholesterol, BMI, SBP, 
LDL, and HDL. Additionally when conductin the analysis using multiple linear 
regression with  the number of sessions attednd, all of the model did not show any 
statisticall significant change in CVD risk factors. The small sample size could explain 
this statistically insignificant result in both groups. Further, it seems other variables, not 
captured in our data, contributed to this change as mentioned previously such as 
medication, patient lifestyle, and duration of the program. Further research should be 
conducted to interpret the change in clinical measures.   
Even though these results were not statistically significant, clinical 
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improvements was noted in total cholesterol levels and LDL. In our study, reduction in 
cholesterol was of clinical significance among the adherent group, with a reduction of 
10%. This result was supported by literature where a previous meta-analysis reported 
that a reduction of 10% in total cholesterol is associated with a significant reduction of 
15% in coronary heart disease-related mortality and a reduction of 11% in the risk of 
all-cause mortality (39, 54). In our study there was a reduction of 15% in LDL level. A 
systematic review and meta-analysis showed that a reduction of 7.2% in LDL is 
clinically significant in reducing coronary heart deaths, and a reduction of 4.4% in total 
LDL level is associated with a reduction in total deaths (40).  
Among non adherent group, LDL showed a clinically significant reduction of 
16% wich is 1% higher  than  adherent group. This reduction could be explained that 
non adhering patients have better educational level, married or they had a netweok 
support by their spouse who might have encouraged them to adher to medications as 
well as supporting their belovedemotionally and sociallyat home, or it could be that 
non-adherents had healthy habits, or were knowledge seekers; once they had the 
information on how to exercise, they prefer to implement at home. 
The qualitative study done in Qatar showed the major reason for not attending 
the sessions is because people believe they can do these exercises at home and take 
good care of themselves(13) this could also justify why non adherent group had this 
good reduction in LDL level.  
6.3 Strength and limitations  
To the best of our knowledge, this is the first study conducted in Qatar to 
establish an association between patients’ factors and adherence to CR program. 
Therefore, our study provided essential information about the characteristics of non- 
non-adherent patients eligible to the CR program in Qatar.  
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The study has few limitations that findings should be interpreted with caution. 
First, the nature of the data and study design (cross sectional) that cannot establish a 
causation between adherence and improvement.  Second,  lack of critical patient data 
affecting adherence (e.g., social support, educational level, transportation, employment, 
marital status, family support, physical activity, and medication) could affect the 
change in risk factors as well as adherence, i.e.ore informative results on factors 
associated with adherence would be revealed if these variables been involved (32, 48, 
50, 55-59). Finally, Systolic blood pressure readings were only pre/post the program 
without having continuous reading throuought the program. Thus it was challenging to 
assess the change in SBP with the number of sessions attended. 
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CHAPTER 7: CONCLUSION 
In summary, the current study unveiled just the tip of the iceberg of patient 
factors associated with enrollment in and adherence to CR program, along with the 
change in clinical cardiac measures [risk factors].  
In conclusion, patient factors predicting adherence were percutaneous coronary 
intervention (PCI), musculoskeletal disease, and AVVCPR risk category. Factors 
positively associated with enrollment were nationality, coronary artery bypass grafting 
(CABG), and coronary artery disease (CAD), whereas factors negatively associated 
with enrollment were back pain, diabetes mellitus, body mass index, and hypertension. 
Cholesterol and low-density lipoproteins had a clinical improvement among adhered 
patients with 10% and 15% reduction, respectively. These patient-level variables 
associated with enrollment and adherence represent opportunities for targeted 
interventions to improve CR enrollment and adherence to get the benefit of the 
program. 
7.1 Recommendation and research implications  
Cardiac rehabilitation is a guideline-recommended strategy structured for the 
management of CVD. Despite its well-documented benefits, it is vastly underutilized.  
The current findings add to a growing body of literature on patient factors associated 
with adherence to the program to help policy makers tailoring their resources and effort 
in addressing these patients to get the benefit of adhering to the  CR program including 
reduction in morbidity and mortality.  
Research is needed to understand patient factors associated with enrollment in 
the program as we were unable to assess it due to lack of data. We recommend to re-
conduct this study to identify variables associated with enrollment as well as 
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reconducting this study but includingcritical variables associated with adherence, such 
as education, employment status, social support, and social status. Additionally, we 
recommend the program directors to adopt strategies that underline a longer follow up 
of patients after discharge, so other studies can be conducted to identify benefit of CR 
program on hard outcome like mortality. A combination of quantitative and qualitative 
research on why people drop out of the program or what could be the reasons Qatari 
patients do not adhere to such programs could be a good future study in this area.  
Finally, a systematic reporting method to report patient's data in the Cerner is highly 
recommended to generate data of good quality that can be used for conducting future 
research to evaluate the effectiveness of the program.   
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